5 Best Mid Cap Stocks To Buy In 2022

1. Globus Medical, Inc. (NYSE:GMED)

Market Capitalization as of February 15: $​​6.846 billion

Number of Hedge Fund Holders: 37

Globus Medical, Inc. (NYSE:GMED) is a company that manufactures medical devices for surgeons to treat patients with musculoskeletal disorders. A total of 37 hedge funds were bullish on Globus Medical, Inc. (NYSE:GMED) in Q3 2021, up from 35 funds in the prior quarter. Polar Capital held the largest stake in Globus Medical, Inc. (NYSE:GMED) as of September 2021, with 714,037 shares worth $54.71 million. 

On January 21, UBS analyst Matthew Taylor kept a Buy rating and a $91 price target on Globus Medical, Inc. (NYSE:GMED) as part of a broader research note on Medical Supplies and Devices. Market surveys according to the analyst suggest that Globus Medical, Inc. (NYSE:GMED) is set to gain the highest market share in the sector.

Here is what Madison Small Cap Fund has to say about Globus Medical, Inc. (NYSE:GMED) in their Q4 2020 investor letter:

“Healthcare continued its streak of underperformance in the fourth quarter. The biotech industry component of the Russell 2000 was up 34% for the quarter and 53% for the year. While we have become more open to investing in this space where appropriate, we prefer molecular diagnostics given less regulatory risk and better revenue diversification. With the new administration comes a shift in healthcare philosophy. We believe that further access to care and coverage expansion will benefit some parts of the sector. However, the risk of further reimbursement cuts, particularly in pharmaceuticals, will bear monitoring.

Our favorite healthcare stock for 2021 is Globus Medical, a provider of spine implants and robotic solutions in the orthopedic industry. This stock has been a disappointing investment in the three years that we have held it. Though, the company itself has executed extremely well. We think this name is a “coiled spring” in a reopening scenario as management played aggressive offense in 2020. They aggressively have grown their sales force and did not hunker down during the pandemic. Recent quarters suggest that the company has taken considerable share, and this should bear fruit as surgical volumes resume in 2021 and 2022.”

You can also take a look at 10 Best Fertilizer Stocks To Buy Now and 10 Best Monthly Dividend Stocks to Buy for 2022.

Follow Insider Monkey on Twitter